Cellectar to present Phase 2 iopofosine data at WM workshop
Tweet Send to a Friend
Cellectar Biosciences (NASDAQ: CLRB) announced it will present a subset analysis from its Phase 2 CLOVER WaM clinical trial at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




